MedTrace Logo

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma

NCT06303583 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-03-12

No results posted yet for this study

Summary

The purpose of study is to investigate the safety and efficacy of sequential immunotherapy with neoadjuvant chemoradiotherapy for esophageal cancer

Conditions

Interventions

DRUG

paclitaxel

paclitaxel, 50 mg/m2, QW\*5

DRUG

carboplatin

area under the curve of2mg/mL/min, QW\*5

DRUG

tislelizumab

200mg Q3W, 2cycles

RADIATION

radiotherapy

41.4Gy in 23 fractions

Sponsors & Collaborators

  • Qiu Guoqin

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2024-08-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06303583 on ClinicalTrials.gov